# MK-3475 as Maintenance Therapy in Extensive Stage SCLC

> **NCT02359019** · PHASE2 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 45 (actual)

## Conditions studied

- Extensive Stage Small Cell Lung Carcinoma

## Interventions

- **BIOLOGICAL:** Pembrolizumab
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT02359019
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2018-10
- **Final completion:** 2018-10
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2022-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02359019

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02359019, "MK-3475 as Maintenance Therapy in Extensive Stage SCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02359019. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*